# Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic Malignancies

> **NCT05240690** · PHASE1 · UNKNOWN · sponsor: **Zhou Fuxiang** · enrollment: 27 (estimated)

## Conditions studied

- Stage IV Pancreatic Cancer
- Hepatocellular Carcinoma , Cholangiocarcinoma

## Interventions

- **BIOLOGICAL:** Umbilical Cord Blood Derived MAK Immune Cells

## Key facts

- **NCT ID:** NCT05240690
- **Lead sponsor:** Zhou Fuxiang
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-07
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2022-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05240690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05240690, "Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05240690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*